Trial · NCT03697512
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
NCT03697512, Phase 2, Active not recruiting, International Extranodal Lymphoma Study Group (IELSG)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas. Trials, record NCT03697512. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03697512
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
- NCT number
- NCT03697512
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 175 participants, actual
- Lead sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Conditions
- Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
- Interventions
- Ibrutinib, Rituximab
- First posted
- 2018-10-05
- Last updated
- 2026-04-08
- Other registries' IDs
- eudract:2018-002364-44
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate at 12 months | 12 months after treatment start | The proportion of patients with complete response after 12 months from treatment start |
| Primary | Progression Free Survival at 5 years | 5 years from treatment start | The proportion of patients without disease progression after 5 years from treatment start |
| Secondary | Number of treatment-Emerging Adverse Events | From the time of informed consent signature until 28 days after treatment discontinuation or until resolution of all treatment-related AEs, whichever occurs later | Analysis of incidence, severity and relationship of adverse events graded according to NCI Common Toxicity Criteria, version 4.0 |
| Secondary | Complete Response Rate at 24 months | 24 months from treatment start | The proportion of patients with complete response after 24 months from treatment start |
| Secondary | Overall Response Rate at 12 and 24 months | 12 and 24 months after treatment start | The proportion of responding patients (partial and complete responses) assessed at 12 and 24 months after treatment start |
| Secondary | Overall survival | From the date of treatment start to the date of death due to any cause until 5 years from treatment discontinuation | The time from the date of treatment start to the date of death from any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40550489 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03697512
GET https://conductscience.org/api/trials/v1/NCT03697512/registered